NCT03209401
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Patients must have DNA damage repair germline (inherited) or somatic mutations. See trial for all eligible mutations
Exclusions: Known or suspected CNS metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03209401